Skip to main content
SpringerLink
Log in

CYFRA 21-1 as a tumor marker used in measuring the serum fragment of cytokeratin subunit 19 by immunoradiometric assay

  • Technical Note
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Serum levels of cytokeratin subunit 19 (CYFRA 21-1) were measured in 42 healthy volunteers, 104 cases of malignant diseases, 30 patients with chronic renal failure and 13 patients with non-malignant and infectious diseases. The reliability of the method was demonstrated after dilution of serum samples and intra- and inter-assay reproducibility. Serum CYFRA 21-1 concentrations were less than 2.00 ng/ml in all healthy controls and 86% of the malignant cases had high serum CYFRA 21-1 levels. However slightly elevated values of CYFRA 21-1 were observed in most chronic renal failure patients. High correlation was observed between serum CYFRA 21-1 and Tissue Polypeptide Antigen (TPA) values (r = 0.90, n = 10) but not with serum alpha-feto protein (AFP) concentrations. Furthermore, cross binding tests with the CYFRA 21-1 tracer/CYFRA 21-1 antibody-coated beads and CYFRA 21-1 tracer/TPA antibody-coated beads also gave an almost linear graph. These results indicate that CYFRA 21-1 and TPA share similar type of antigens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wilson JD, Brounwald E, Isselbacher KJ, Petersdorf RG, Martin JB, Fauci AS, et al. Tumor Markers.In Harison’s Principles of Internal Medicine, Vol. 2, ed. 12: 1586–1587, 1991.

    Google Scholar 

  2. Pujal JL, Grenier J, Daures JP, Daver A, Pujol H, Michel FB. Serum fragment of Cytokeratin Subunit 19 Measured by CYFRA 21-1 Immunoradiometric Assay as a Marker of Lung Cancer.Cancer Res 53: 61–66, 1993.

    Google Scholar 

  3. Luning B, Wiklund B, Redelius P. Biochemical properties of Tissue Polypeptide Antigen.Biochem Biophys Acta 624: 90–101, 1980.

    PubMed  CAS  Google Scholar 

  4. Osborn M, Weber K. Intermediate filament: Cell type specific markers in differentiation and pathology.Cell 31: 303–306, 1982.

    Article  PubMed  CAS  Google Scholar 

  5. Moll R, Franke WW, Schiller DL, Geiber B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells.Cell 31: 11–24, 1982.

    Article  PubMed  CAS  Google Scholar 

  6. Hoefler H, Denk H. Immunohistochemical demonstration of cytokeratins in gastrointestinal carcinoids and their probable precursors cells.Virchows Arch, B Cell Pathol 403: 235–240, 1984.

    Google Scholar 

  7. Moll R, Krepier R, Franke WW. Complex cytokeratin polypeptide patterns observed in certain human carcinomas.Differentiation 23: 256–269, 1983.

    Article  PubMed  CAS  Google Scholar 

  8. Debus E, Moll R, Franke WW, Weber K, Osborn M. Immunohistochemical distinction of human carcinomas by cytokeratin typing with monoclonal antibodies. AmJ Pathol 114: 121–130, 1984.

    PubMed  CAS  Google Scholar 

  9. Blobel GA, Moll R, Franke WW, Vogt-Myokopf I. Cytokeratins in normal and lung carcinomas. Adenocarcinomas, squamous cell carcinomas and cultured cell lines.Virchows Arch, B Cell Pathol 45: 407–429, 1984.

    Article  CAS  Google Scholar 

  10. Cooper D, Schemer A, Sun T-T. Biology of disease: classification of human epithelia and their neoplasms using monoclonal antibodies to keratins: strategies, applications and limitations.Lab Invest 52: 243–256, 1985.

    PubMed  CAS  Google Scholar 

  11. Negle RB, Moll R, Weidauer H, Nemetschek H, Franke WW. Different patterns of cytokeratin expression in the normal epithelia of the upper respiratory tract.Differentiation 30: 130–140, 1985.

    Article  Google Scholar 

  12. Coltrera MD, Zarbo RJ, Gown AM. Comparison of two putative markers of premalignant change in the oral cavity: suprabasal expression of CK-19 and proliferating cell nuclear antigen. Proceedings of the Third International Head and Neck Oncology Research Conference 1990 Sept 26–28, Las Vegas (NV), The American Society for Head and Neck Surgery, Oklahoma City, 1990: 403.

    Google Scholar 

  13. Nicolson GL. Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression.Cancer Res 47: 1473–1487, 1987.

    PubMed  CAS  Google Scholar 

  14. Lindberg K, Rheinwald JG. Suprabasal 40 kd keratin (K 19): expression as immunohistological marker of premalignancy in oral epithelium.Am J Pathol 134: 89–98, 1989.

    PubMed  CAS  Google Scholar 

  15. Cintorino M, Petracca R, Vindigini C, Tripodi SA, Leoncini P. Topography-related expression of individual cytokeratins in normal and pathological (non-neoplastic and neoplastic) human oral mucosa.Virchows Arch [A] 417: 419–426, 1990.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Gunma University School of Medicine and Tano General Hospital, Japan

    Muhammad Sarwar, Katsumi Tomiyoshi, Tomio Inoue, Kazuhiro Fukazawa & Keigo Endo

Authors
  1. Muhammad Sarwar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katsumi Tomiyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tomio Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kazuhiro Fukazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Keigo Endo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sarwar, M., Tomiyoshi, K., Inoue, T. et al. CYFRA 21-1 as a tumor marker used in measuring the serum fragment of cytokeratin subunit 19 by immunoradiometric assay. Ann Nucl Med 8, 301–306 (1994). https://doi.org/10.1007/BF03165035

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03165035

Key words

Search

Navigation